Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

AIDS

Volumn 19, Issue 6, 2005, Pages 630-632

  Wirden, Marc ^a   Malet, Isabelle ^a   Derache, Anne ^a   Marcelin, Anne Genevieve ^a   Roquebert, Benedicte ^a   Simon, Anne ^a   Kirstetter, Myriam ^a   Joubert, Laurence Morand ^b   Katlama, Christine ^a   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS RESISTANCE;

EID: 20244383737     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000163942.93563.fd     Document Type: Article

References (14)

1. Miller M, Margot N, McColl D, Coakley D, Cheng A. Characterization of virologic failure through 96 weeks among treament-naive patients taking tenofovir df (tdf) or stavudine (d4t) in combination with lamivudine (3tc) and efavirenz (efv) [Abstract 553]. Antivir Ther 2003; 8 (Suppl. 1):S333.
2. Jemsek J, Hutcherson P, Harper E. Poor virilogic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: 11th Conference on Retroviruses and Opportunistic infections. San Francisco, USA, 8-11 February 2004 [Astract 51].
3. Landman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus Study. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 8-11 February 2004 [Abstract 52].
4. Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother 2004; 48:1413-1415.
5. Miller M, Margot N, McColl D, Wrin T, Coakley D, Cheng A. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antivir Ther 2003; 8 (Suppl. 1):S151.
6. Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003; 8:173-182.
7. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-expenenced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
8. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949-951.
9. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.
10. Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22-33.
11. Deval J, Navarro JM, Selmi B, Courcambeck J, Boretto J, Halfon P, et al. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004; 279:25489-25496.
12. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi RF, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exibits bi-directional phenotypic antagonism with TAM. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 54].
13. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.
14. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41:757-762.